[Clinical study of patients with primary polyarthritis. Cross-over comparative study of proglumetacin and naproxen].
Proglumetacin at low-dose (300 mg/day) and naproxen (500 mg/day) were used in a crossover study in 20 patients with primary polyarthrosis. Each drug was administered during 1 week without between drugs. Both drugs resulted effective in the management of the most disturbing symptoms, without significant differences. Tolerance was also superimposable, as the few reported complaints were recorded under both treatments and appeared rather related to the patient than to the drug. Proglumetacin therefore, even when given at low dose, resulted at least as effective as an established treatment for polyarthrosis, while confirming its very good tolerance, so as to appear well suited for the general management of patients with such degenerative-reactive disorders.
D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007210:Indoleacetic Acids / Q000627:therapeutic use*; D008875:Middle Aged; D009288:Naproxen / Q000627:therapeutic use*
D007210:Indoleacetic Acids; D009288:Naproxen; C019541:proglumetacin
Studio clinico in pazienti affette da poliartrosi primaria. Confronto in cross-over tra proglumetacina e naproxen.